

# Prostatic Diseases and Male Voiding Dysfunction

## The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial

Bilal Chughtai\*, Dean Elterman\*, Neal Shore, Marc Gittleman, Jay Motola, Sheldon Pike, Craig Hermann, William Terrens, Alfred Kohan, Ricardo R. Gonzalez, Aaron Katz, Jeffery Schiff, Evan Goldfischer, Ivan Grunberger, Le Mai Tu, Mark N. Alshak, and Jed Kaminetzky

<b>OBJECTIVE</b>	To report the results of a multicenter, randomized, controlled trial with a temporarily implanted nitinol device (iTind; Medi-Tate Ltd, Hadera, Israel) compared to sham for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
<b>MATERIALS AND METHODS</b>	Men 50 years or older were randomized 2:1 between iTind and sham procedure arms. A self-expanding, temporary nitinol device was placed for 5-7 days and an 18F Foley catheter was inserted and removed for the iTind and sham group, respectively. Patients were assessed at baseline, 1.5, 3, and 12 months postoperatively using the IPSS, peak urinary flow rate, residual urine, quality of life, and the International Index of Erectile Function. Unblinding occurred at 3 months.
<b>RESULTS</b>	A total of 175 men (mean age $61.1 \pm 6.5$ ) participated (118 iTind vs 57 sham). A total of 78.6% of patients in the iTind arm showed a reduction of $\geq 3$ points in IPSS, vs 60% of patients in the control arm at 3 months. At 12 months, the iTind group reported a 9.25 decrease in IPSS ( $P < .0001$ ), a 3.52ml/s increase in peak urinary flow rate ( $P < .0001$ ) and a 1.9-point reduction in quality of life ( $P < .0001$ ). Adverse events were typically mild and transient, most Clavien-Dindo grade I or II, in 38.1% of patients in the iTind arm and 17.5% in the control arm. No de novo ejaculatory or erectile dysfunction occurred.
<b>CONCLUSION</b>	Treatment with the second-generation iTind provided rapid and sustained improvement in lower urinary tract symptoms for the study period while preserving sexual function. UROLOGY 00: 1–7, 2020. © 2020 Elsevier Inc.

\* Co-first authors (both authors contributed equally to the publication)

Financial Disclosure of Corresponding Author: Bilal Chughtai, MD is a consultant for Medi-Tate Ltd, Olympus, Boston Scientific, and Medeon Bio.

Medi-Tate Ltd. sponsored this study.

From the Department of Urology, NY-Presbyterian Hospital, Weill Cornell Medical Center, New York, NY; the Division of Urology, University Health Network, University of Toronto, Toronto, Ontario, Canada; the Carolina Urology Research Center, Myrtle Beach, SC; the South Florida Medical Research, Miami, FL; the Mt Sinai Hospital, New York, NY; the St John's Episcopal, New York, NY; the Clinical Research Center of Florida, Miami, FL; the Premier Urology Group, New Jersey, NJ; the Integrated Medical Professionals, Long Island, NY; the Houston Metro Urology, Houston, TX; the NYU Winthrop Hospital, Long Island, NY; the Premier Medical Group of the Hudson Valley, Poughkeepsie, NY; the New York Methodist Hospital, Brooklyn, NY; the Sherbrooke University Hospital, Sherbrooke, Quebec, Canada; the Weill Cornell Medical College, New York, NY; and the Manhattan Medical Research, Manhattan, NY

Address correspondence to: Bilal Chughtai, MD, Associate Professor of Urology, Department of Urology, 425 East 61st Street, 12th Floor, New York, NY 10065. E-mail: bic9008@med.cornell.edu

© 2020 Elsevier Inc.  
All rights reserved.

Benign prostatic hyperplasia (BPH) is often associated with bothersome lower urinary tract symptoms (LUTS) affecting 50%-75% in men over 50, and reach up to 80% in men aged 70 years and older with adherence rates to pharmacology as low as 30% after one year due to unmet due to unmet patient expectations or bothersome side effects.<sup>1-5</sup> Treatment-induced sexual dysfunction is a key concern when considering pharmaceutical therapy.<sup>3,6,7</sup>

Transurethral resection of the prostate (TURP), considered the "gold-standard" in surgical therapy for LUTS secondary to BPH, provides significant and durable relief of symptoms. However, it incurs the risk of significant postprocedural morbidity and long-term complications,

<https://doi.org/10.1016/j.urology.2020.12.022>

0090-4295

including urinary incontinence (3%), strictures (7%), erectile dysfunction (10%), and loss of ejaculation (65%), and 20%-50% persistent LUTS.<sup>8,9</sup> Novel laser-based ablative modalities provide effective relief of BPH-related symptoms with a similar rate of complications as TURP.<sup>8,10</sup>

Among effective, minimally invasive alternatives for LUTS secondary to BPH treatment such as the prostatic urethral lift (PUL, UroLift System, Extract, CA)<sup>11</sup> and convective water vapor treatment (Rezum System, NxThera, Maple Grove, MN), the second-generation temporarily implanted nitinol device (iTind; Medi-Tate Ltd, Hadera, Israel)<sup>11</sup> was given de novo authorization by the Food and Drug Administration (FDA) in February 2020. Two single-arm studies have demonstrated that iTind treatment provides rapid and effective LUTS relief that is durable to 3 years, with low rates of adverse events (AEs) and preservation of sexual function.<sup>12,13</sup> This study compares iTind to sham in the reduction of LUTS secondary to BPH.

## MATERIALS AND METHODS

### Study Protocol and Objectives

This prospective, randomized, controlled, single-blinded study of the second-generation iTind procedure was conducted at 16 sites in the US and Canada in men with symptomatic BPH. The FDA and Health Canada approved the study, as did institutional review boards at each of the enrolling sites ([Clinicaltrials.gov: NCT02506465](https://clinicaltrials.gov/ct2/show/study/NCT02506465)). Written informed consent was obtained from all participants.

Subjects eligible and enrolled for the study included: men  $\geq$  50 years, IPSS (International Prostate Symptoms Score) of  $\geq$  10, peak urinary flow rate (PFR) of  $\leq$  12 mL/sec with a 125 mL voided volume, prostate volume between 25 and 75 cc, and normal urinalysis, complete blood count, and biochemistry. Excluded patients had a postvoid residual volume (PVR)  $>$  250 mL, obstructive median lobe (OML), prostate specific antigen (PSA)  $>$  10 ng/mL or free PSA  $<$  25%, without a subsequent negative prostate biopsy, previous prostate surgery, prostate or bladder cancer, neurogenic bladder and/or sphincter abnormalities, or confounding bladder pathologies based on medical history, recent cystolithiasis or hematuria, active UTL, compromised renal function, severe respiratory disorders, known immunosuppression, active antithrombotic or antiplatelet treatment, cardiac disease, including arrhythmias and uncontrolled diabetes mellitus. Ultrasound was carried out pre-operatively to evaluate for OML and IPP was measured. Cystoscopy was not mandatory during screening, but cystoscopy was used during placement of the device and an intra-operative exclusion criterion of OML existed.

Baseline medical history, BPH-related medications, uroflowmetry, IPSS, PVR, and completion of questionnaires regarding quality of life (QoL), erectile, and ejaculatory function was collected before the procedure. All patients on BPH-related medications started a wash-out period prior to implantation: 1 month for alpha-blockers and 6 months for 5-alpha-reductase inhibitors. Medication naïve patients seeking treatment refused medication in preference for a minimally invasive surgical technique.

### iTind Procedure

The iTind implantation has been described in previous studies.<sup>12,13</sup> Briefly, the iTind device is comprised of three elongated, intertwined nitinol struts at the 12, 5, and 7 o'clock positions, an anti-migration anchoring leaflet at 6 o'clock, and a polyester retrieval suture for easy device removal.

The device is implanted for 5-7 days, during which it expands and exerts radial force, creating deep ischemic incisions, and a remodeling on the prostate tissue at the bladder neck and anterior prostatic fossa. The iTind is deployed under direct visualization in an ambulatory procedure using a rigid cystoscopy. The device is removed through either a rigid cystoscope or an open-ended 22F Foley catheter with topical anaesthesia. Both implantation and removal can be done under local, IV, or general anaesthesia at the discretion of the performing physician. Catheterisation is not required following either implantation or removal.

### Sham Procedure

The sham control was the insertion and removal of an 18F silicon Foley catheter in order to simulate both the implantation and retrieval procedures. Throughout the procedure, the surgeon gave verbal description as if deploying the iTind device, after which the catheter was removed. A similar protocol was followed for the removal. Although the iTind device is deployed through a rigid cystoscope, a Foley catheter was used to minimize the risk of procedure-related morbidity. Subjects in both the device and control groups were draped to prevent them from seeing the treating physician and the device.

### Statistical Methodology

Subjects were randomized in 2:1 ratio to either iTind or control groups using permuted blocks stratified by center by using a central electronic data program. Analysis suggested that for an expected response rate of 75% in iTind and 51% in sham (24% difference), using a 5% 2-tailed Fisher exact test, a total of 180 subjects randomized to either iTind or sham will provide at least 85% power to meet the study primary endpoint.

The primary endpoint compared the percentage of patients achieving a reduction of at least 3 points in IPSS at 3 months, between iTind and control groups, in accordance with the FDA guideline for BPH treatments, published in 2010, the most recent guidance available at the time of the study. Similar to other randomized controlled trials, unblinding of the sham arm occurred at 3 months.<sup>14,15</sup> The ITT analysis used logistic regression with baseline IPSS, diagnosis of BPH at baseline, prostate volume, and PSA as covariates. Missing IPSS were imputed using multiple imputations under the "missing at random" assumption. The imputed model included treatment group, country/geographical region pre-study diagnosis of BPH, baseline prostate volume, and PSA. Missing prostate volume and PSA were imputed for 2 patients based on baseline values of PFR, PVR, IPSS, IIEF, SHIM, and BPH. Patients who discontinued the study due to AEs or initiation of alternative treatments were considered treatment failures and were imputed as a worst-case imputation, which is a baseline value for all missing evaluations. The responder analysis was also carried out at 12 months to evaluate durability of effect.

All secondary endpoints were analyzed descriptively in the per protocol analysis set of eligible patients.

Statistical analysis was done using SAS 9.4 (SAS Institute Inc., Cary, NC). Statistical significance was accepted at  $P$ -value  $<$  .05.

## RESULTS

## Procedure

A total 185 men (mean age  $61.1 \pm 6.5$  years, mean BMI  $28.8 \pm 5.7$  kg/m<sup>2</sup>) were randomized 2:1 and assigned to either treatment with iTind ( $n = 128$ ) or sham control ( $n = 57$ ) in 16 centers (14 in the United States, 2 in Canada) between July 2015 and October 2018 (Table 1). Baseline demographics were similar among randomized groups, except for the Charlson Comorbidity Index, with iTind having a higher score (2.52 v. 1.26,  $P < .001$ ) (Table 1). All sites had no prior experience with iTind. Notably, 213 screen failure events occurred, the majority of which were due to not meeting the inclusion criteria. Three were due to patients refusing a wash-out of 5-alpha-reductase inhibitors (6mos). 10 men did not undergo the iTind procedure, resulting in a final cohort of 118. Reasons for loss of follow-up can be found in Figure 1. Medication naïve patients seeking treatment refused medication in preference for a minimally invasive surgical technique. No cases were excluded intra-operatively due to OML.

## Efficacy

The primary endpoint of improvement of IPSS  $\geq 3$  determining the effectiveness of the iTind treatment was achieved at 3 months in 78.6% of iTind patients compared to 60% of patients in the control arm, a difference of 18.6% ( $P = .029$ ). The responder analysis of improvement of IPSS  $\geq 7$  showed that iTind still had a responder's rate of 72.6% vs 50% in the sham arm ( $P = .048$ ). A durable responder rate in 79% of patients was demonstrated out to 12 months ( $P = .009$ ). Of note, 97% of patients that responded to treatment at 3 months remained responders at 12 months.

At the time of unblinding at 3 months, in the ITT patient population, iTind improved IPSS by  $-9.0 \pm 8.5$  (22.1-13.0) while the sham arm improved  $-6.6 \pm 9.5$  (22.8-15.8) ( $P = .063$ ). iTind and sham also demonstrated an improvement in QoL in the ITT patient population, with a reduction from  $4.6 \pm 1.3$  at baseline to  $2.7 \pm 1.8$  at 3 months, vs  $4.9 \pm 1.0$ - $3.4 \pm 2.0$  in the sham arm, respectively ( $P = .264$ ). Similarly, PFR improved from  $8.7 \pm 3.3$  mL/s to  $13.1 \pm 7.1$  mL/s in the iTind arm vs  $8.5 \pm 2.4$  mL/s- $11.4 \pm 5.3$  mL/s in the sham arm at 3 months ( $P = .230$ ). Additionally, PVR improved from  $60.78 \pm 56.35$  mL to  $59.44 \pm 56.43$  mL in the iTind arm vs  $61.9 \pm 54.2$  mL- $66.9 \pm 65.1$  mL in the sham arm at 3 months ( $P = .781$ ). Sexual function according to the IIEF and SHIM questionnaires remained unchanged in both groups.

Secondary endpoints in the iTind arm showed a significant reduction in IPSS urinary symptoms at 12 months from  $22.64 \pm 6.8$  at baseline to  $12.69 \pm 6.35$ ; a reduction of  $-9.25 \pm 6.49$  points in the per protocol population ( $P < .0001$ ) (Table 2). Of note, patients that were severely symptomatic at baseline (IPSS of 20-35) reported a similar level of improvement at 12 months to those that were moderately symptomatic (IPSS of 8-19), with a reduction of 41.5% vs 39%, respectively.

QoL score was reduced from  $4.51 \pm 1.24$  to  $2.45 \pm 1.79$  ( $-1.9 \pm 1.74$ ) at 12 months ( $P < .0001$ ), and PFR also increased from  $8.42 \pm 2.09$  mL/s to  $11.93 \pm 4.89$  mL/s ( $3.52 \pm 5.24$  mL/s) ( $P < .0001$ ) (Table 2).

PVR only significantly decreased at the 1.5-month follow-up ( $65.08 \pm 60.66$ - $49.90 \pm 55.82$ ,  $P = .0244$ ) but did not decrease with any clinically significant change from baseline at 3 months and 12 months among men who voided at least 125cc (Table 2).

Six men (4.7%) had an alternative BPH surgery during the 12-month follow-up due to deterioration of symptoms. iTind did not complicate any of the alternative surgeries. An additional 6 men (4.7%) required medication for LUTS secondary to BPH (Fig. 1).

## Safety

In the iTind group, a total of 5 procedure- and/or device-related SAEs were observed in 3 patients, including urinary retention ( $n = 2$ ), UTI ( $n = 2$ ), and sepsis ( $n = 1$ ) (Table 3). Urinary retention, UTI, and sepsis did not occur in the sham arm. Only 3 SAEs from 2 patients during the post retrieval phase were found to be possibly related to the device. One patient died from an unrelated pancreatic cancer complication, as adjudicated by clinical events committee and data monitoring committee. iTind had more overall AEs as compared to the sham group within the first 30 days (38.1% vs 17.5%). 68% of AEs occurred within 7 days of treatment (while the device was in the body). Most were mild, anticipated, and all but 2 resolved within 1-4 weeks. Dysuria occurred in 22.9% of men and hematuria in 13.6% in the iTind arm compared to 8.8% and 0% in the sham arm within the first 30 days. None of the 118 subjects experienced *de novo* erectile or ejaculatory dysfunction (Table 2). SHIM for patients at baseline was  $12.92 \pm 7.49$  with no change at 1.5, 3, or 12 months ( $P = .8165$ ,  $P = .7078$ , and  $P = .3155$ , respectively) and IIEF at baseline for patients was  $36.86 \pm 20.04$  with no change at 1.5 and 3 months ( $P = .0738$  and  $P = .0523$ ) with an increase in score of  $4.51 \pm 18.10$  at 12 months

**Table 1.** Baseline Demographics

Characteristic	iTIND			Sham			P-Value
	N	Mean	SD	N	Mean	SD	
Age (years)	128	61.5	6.5	57	60.1	6.3	<b>0.1284</b>
Height (ft)	128	5.7	0.35	57	5.8	0.32	<b>0.0672</b>
Weight (lbs)	128	194	41.2	57	198	42.7	<b>0.5473</b>
BMI	128	28.8	5.7	57	28.8	5.5	<b>1</b>
CCI	128	2.52	1.6	57	1.26	0.7	<b>&lt;.0001</b>
Prostate Volume	127	43.4	15.5	56	43.8	13.3	<b>0.867</b>
IPSS	127	22.1	6.8	57	22.8	6.2	<b>0.5081</b>
Qmax	125	8.7	3.3	56	8.5	2.4	<b>0.6841</b>
PVR	125	61.6	55.5	56	61.9	54.2	<b>0.9730</b>
QoL	127	4.6	1.3	57	4.9	1	<b>0.1234</b>
PSA	126	2.2	2.3	56	1.8	1.8	<b>0.2503</b>
IIEF	125	38.3	20.7	57	39.1	19.6	<b>0.8061</b>
SHIM	127	13.2	7.3	57	14.2	6.6	<b>0.3776</b>




Figure 1. CONSORT flow diagram.

( $P = .0101$ ) (Table 2). All procedures were performed without serious perioperative AEs.

The iTind implantation procedure was well tolerated, with a mean post-procedural VAS pain score of 4.2 (SD: 3.1) vs 1.0 (2.2) for the sham arm. Removal of iTind had a mean VSAS score of 3.3 (3) vs 2 (2.1) in the sham arm. iTind implantation procedures were performed under IV sedation ( $n = 77$ , 66.1%), local anesthetic ( $n = 32$ , 27.1%), or general anesthesia ( $n = 8$ , 6.8%). iTind removal was performed under IV sedation ( $n = 71$ , 60.2%), local anesthetic ( $n = 29$ , 24.6%), or general anesthesia ( $n = 3$ , 2.5%). Sham procedure was performed under IV sedation (49.2%), local anesthetic (49.2%), or general anesthesia (1.8%). All patients were discharged day of procedure. iTind patients reported a return-to-preoperative-activity level of  $5.2 \pm 17.0$  days after device retrieval, compared to  $3.5 \pm 4.4$  days for control. None of the subjects in the iTind arm underwent routine postoperative catheterization, with only 7 (5.9%) of patients in the iTind arm experiencing an episode of urinary retention.

## DISCUSSION

The results of this randomized, controlled, single-blinded, double-arm prospective study on the iTind device demonstrate improvements in IPSS of  $-9.0 \pm 8.5$  points (40.1%)

at 3 months. These results substantiate previous prospective studies on iTind that showed reductions in IPSS at 3 months of 11 points and 12.6 points, respectively.<sup>12,13</sup> This improvement in IPSS is similar to other minimally invasive devices. PUL demonstrated a reduction in IPSS of 11.1 points at 3 months, and Rezum demonstrated a similar reduction of 11.3 points in the same follow-up period.<sup>14,15</sup> Additionally, iTind showed a mean improvement in PFR of 4.4 mL/s at 3 months, which is also consistent with PUL and Rezum results.<sup>14,15</sup>

Treatment with iTind demonstrated to be durable for 12 months. IPSS improvement was maintained with a mean reduction of  $-9.25 \pm 6.49$  points from baseline, and PFR, with an average increase of  $3.52 \pm 5.24$  mL/s from baseline. Men with severe or moderate symptoms at baseline had similar rates of improvement at 12 months. Only 4.7% of patients underwent another surgical intervention for BPH during the follow-up period. Previous studies have demonstrated similar results. In the first study, no patients required surgical intervention for BPH after 3 years, and the second study presented a total, accumulated re-intervention rate of 8.6% at 2 years of follow-up following iTind placement.<sup>12,13</sup>

**Table 2.** Summary of functional results during 12 months follow-up (PP Analysis Set)

Endpoint	1.5 Month	3 Months	12 Months
<b>IPSS Urinary Symptoms Score</b>			
N, paired	96	80	78
Baseline	22.37 ± 6.92	22.38 ± 6.84	21.64 ± 6.80
Follow up	12.80 ± 7.40	12.57 ± 6.95	12.69 ± 6.35
Change	-9.57 ± 8.29	-9.48 ± 8.49	-9.25 ± 6.49
95% CI	(-11.3 to -7.9)	(-11.4 to -7.6)	(-11.0 to -7.4)
P value	<.0001	<.0001	<.0001
<b>IPSS QoL</b>			
N, paired	96	80	78
Baseline	4.66 ± 1.31	4.55 ± 1.27	4.51 ± 1.24
Follow up	2.83 ± 1.88	2.54 ± 1.82	2.45 ± 1.79
Change	-1.83 ± 1.97	-1.96 ± 1.86	-1.90 ± 1.74
95% CI	(-2.2 to -1.4)	(-2.3 to -1.4)	(-2.2 to -1.4)
P value	<.0001	<.0001	<.0001
<b>Qmax (mL/s)</b>			
N, paired	73	65	55
Baseline	8.01 ± 2.21	8.63 ± 2.71	8.42 ± 2.09
Follow up	13.33 ± 10.50	13.55 ± 6.40	11.93 ± 4.89
Change	5.32 ± 10.33	5.01 ± 6.39	3.52 ± 5.24
95% CI	(2.9 to 7.7)	(3.4 to 6.6)	(2.0 to 5.0)
P value	<.0001	<.0001	<.0001
<b>PVR (mL)</b>			
N, paired	73	65	55
Baseline	65.08 ± 60.66	60.78 ± 56.35	57.62 ± 56.16
Follow up	49.90 ± 55.82	59.44 ± 56.43	58.67 ± 72.36
Change	-15.26 ± 63.88	-2.20 ± 56.59	-0.16 ± 87.01
95% CI	(-30.3 to -0.3)	(-16.7 to 12.3)	(-24.6 to 24.3)
P value	0.0244	0.7407	0.9039
<b>SHIM</b>			
N, paired	96	80	78
Baseline	12.92 ± 7.49	13.40 ± 7.26	14.03 ± 7.41
Follow up	12.83 ± 8.06	13.70 ± 7.76	14.25 ± 7.45
Change	-0.10 ± 7.00	0.40 ± 7.20	0.45 ± 5.95
95% CI	(-1.5 to 1.3)	(-1.2 to 2.0)	(-1.0 to 1.9)
P value	0.8165	0.7078	0.3155
<b>IIEF</b>			
N, paired	96	80	77
Baseline	36.86 ± 20.04	39.28 ± 19.91	40.01 ± 19.76
Follow up	40.31 ± 22.40	43.52 ± 22.24	43.75 ± 19.85
Change	3.47 ± 18.56	3.83 ± 19.61	4.51 ± 18.10
95% CI	(-0.4 to 7.3)	(-0.7 to 8.3)	(0.2 to 8.8)
P value	0.0738	0.0523	0.0101

Change from baseline was evaluated using general estimating equation model (GEE) with baseline value and visit as predictors. Exchangeable correlation structure and identity link were used.

For Qmax and PVR, only tests in which the voided volume was 125cc or greater were included in the analysis.

For subjects who had an intervention recorded, all visits following the intervention were excluded from the analysis.

Importantly, the iTind procedure can be conducted with the patient under sedation or local anesthesia in an ambulatory or office setting, with almost 50% of patients being treated in the clinic outpatient setting. Our study also supports iTind placement is a catheter-free procedure, with only 7 patients experiencing self-resolving urinary retention. Most patients returned to their pre-operative activity level within 5 days from the retrieval of the device.

Preservation of ejaculatory function is of major importance to men when pursuing treatments for LUTS secondary to BPH.<sup>17</sup> TURP is associated with rates of retrograde ejaculation of 38.2%-89.0% and impotence rates of 13.0%-14.0%, while laser prostatectomy has retrograde ejaculation rates of 50%-76.6% and impotence rates of

5.2%-7.9%.<sup>18</sup> Both surgical and pharmacologic sexual side effects contribute to the undertreatment of men with BPH.<sup>3,6,7</sup> One major advantage of the iTind procedure is the preservation of sexual function. No iTind subjects experienced de novo erectile dysfunction or retrograde ejaculation. This is similar to a recent prospective study showing sexual function was preserved in all iTind subjects at 6 months of follow-up.<sup>19</sup>

AEs were limited to mild events at a low rate. Medication-use was low, with only one patient complaining of pain. Our low-rate of SAEs is important, given that TURP can lead to as much as 9% of cases (blood transfusion, sepsis, and deep venous thromboembolism, etc.).<sup>20,21</sup> Importantly, our observed procedure-related AEs were also less than that with other transurethral

**Table 3.** Overview of adjudicated adverse events

	iTind Group 0-30 days			Sham Group 0-30 days			iTind Group 1-3 months			iTind Group 3-12 months		
	Events (n)	Subjects (n)	Subjects (%)	Events (n)	Subjects (n)	Subjects (%)	Events (n)	Subjects (n)	Subjects (%)	Events (n)	Subjects (n)	Subjects (%)
Serious AEs	16	10	7.8	2	2	3.5						
Related serious	5	3	2.3									
All AEs	109	45	38.1	19	10	17.5						
Related AEs	81	39	33.1	4	4	7	2	2	1.6	1	1	0.8
Dysuria	27	27	22.9		5	8.8						
Hematuria	16	16	13.6									
Micturition urgency	6	6	5.1		1	1.8						
Pollakiuria	8	8	6.8		1	1.8						
Urinary retention	7	7	5.9				1	1	0.8			
Urinary tract infection	2	2	1.7				1	1	0.8			
Sepsis	1	1	0.8									
Pain	1	1	0.8									

procedures, with 33.1% of patients experiencing an AE, vs 38% of Rezum patients and 80% of PUL patients. Less SAEs (dysuria, hematuria, pollakiuria, micturition urgency) were comparable to other minimally invasive endourological therapies as well as standard cystoscopy.<sup>14,15</sup> The most common AEs with iTind were dysuria (22.9%) and hematuria (13.6%), PUL had dysuria and hematuria rates of 34.3% and 25.7% while Rezum had dysuria and hematuria rates of 16.9% and 11.8%, respectively. The absence of the need for postoperative catheterization also results in a lower rate of UTIs with an incidence of 1.7% vs 2.9% with PUL and 3.7% with Rezum.<sup>14,15</sup> As shown in earlier trials, since no device is left in the body long-term, there is nothing to complicate future MRI-guided prostate biopsy, and no risk of delayed AEs out to 12 months.<sup>12,13</sup>

Our study has several limitations. First, we had a loss of follow-up between the baseline groups at the 3-month visit of 29% of patients in the iTind arm, and 30% of patients in the sham arm, which may have skewed the results. While our lost to follow-up was high, there was a matched dropout rate between the iTind and sham arm, showing that this was likely not a procedure-related drop-off. Missing values for various endpoints were filled in using the “missing at random” assumption to help overcome this. Moreover, because our study included specific inclusion criteria in regards to age, IPSS, PFR, and prostate volume, our results are not generalizable to all men with LUTS secondary to BPH. Furthermore, our study did include a powerful placebo effect that resulted in non-statistically significant improvement in iTind versus the sham arm at the time of unblinding at 3 months. This can partly be explained by the brain’s response to treatment, including a sham procedure.<sup>22</sup> Moreover, a meta-analysis found significant improvements in AUA-SS and Qmax at 3 months in the sham arm of randomized controlled trials in BPH trials.<sup>23</sup> AUA-SS improved an average of 27%, similar to our improvement in IPSS of 28.9% in our sham arm. While our sham effect is large, this improvement is similar to PUL’s sham arm improvement of 24.2% and Rezum’s sham arm improvement of 20%.<sup>14,16</sup> Strengths of our study include that it was randomized, blinded, and conducted at 16 sites comprised of a variety of types of care facilities, from offices to university hospitals who all had no previous experience with the procedure.

**CONCLUSION**

iTind provides a safe, rapid, and sustained improvement in LUTS to 12 months secondary to BPH in prostate volumes of 25-75cc. This minimally invasive FDA-approved procedure is effective and well tolerated for LUTS treatment, while preserving both ejaculation and erectile function, and offers patients an attractive alternative for relief of symptomatic BPH.

**References**

1. Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident

- rates. *Urol Clin North Am.* 2016;43:289–297. <https://doi.org/10.1016/j.ucl.2016.04.001>.
2. Schoenfeld MJ, Shorridge EF, Gelwicks SC, Cui Z, Wong DG. Treatment patterns in Alpha-Blocker therapy for benign prostatic hyperplasia. *Am J Mens Health.* 2014;8:267–272. <https://doi.org/10.1177/1557988313510732>.
  3. Cindolo L, Pirozzi L, Fanizza C, et al. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. *Eur Urol.* 2015;68:418–425. <https://doi.org/10.1016/j.eururo.2014.11.006>.
  4. Fourcade R-O, Lacoïn F, Rouprêt M, et al. Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia. *World J Urol.* 2012;30:419–426. <https://doi.org/10.1007/s00345-011-0756-2>.
  5. Emberton M. Medical treatment of benign prostatic hyperplasia: physician and patient preferences and satisfaction. *Int J Clin Pract.* 2010;64:1425–1435. <https://doi.org/10.1111/j.1742-1241.2010.02463.x>.
  6. Kelly-Blake K, Holmes-Rovner M, Lillie J, et al. Older men and sexual function: is BPH treatment a high stakes decision? *Int J Men's Health.* 2006;5:93.
  7. Helgason AR, Adolffson J, Dickman P, et al. Sexual desire, erection, orgasm and ejaculatory functions and their importance to elderly Swedish men: a population-based study. *Age Ageing.* 1996;25:285–291. <https://doi.org/10.1093/ageing/25.4.285>.
  8. McVary KT, Roehrborn CG, Avins AL, et al. American urological association guideline: management of benign prostatic hyperplasia (BPH). *American Urological Association Education and Research Inc.* 2010:17–22.
  9. Kim SJ, Al Hussein Alawamlh O, Chughtai B, Lee RK. Lower urinary tract symptoms following transurethral resection of prostate. *Curr Urol Rep.* 2018;19:85. <https://doi.org/10.1007/s11934-018-0838-4>.
  10. Thangasamy IA, Chalasani V, Bachmann A, Woo HH. Photoselective vaporisation of the prostate using 80-W and 120-W laser versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review with meta-analysis from 2002 to 2012. *Eur Urol.* 2012;62:315–323. <https://doi.org/10.1016/j.eururo.2012.04.051>.
  11. Chung ASJ, Woo HH. Update on minimally invasive surgery and benign prostatic hyperplasia. *Asian J Urol.* 2018;5:22–27. <https://doi.org/10.1016/j.ajur.2017.06.001>.
  12. Porpiglia F, Fiori C, Bertolo R, et al. 3-Year follow-up of temporary implantable nitinol device implantation for the treatment of benign prostatic obstruction. *BJU Int.* 2018;122:106–112. <https://doi.org/10.1111/bju.14141>.
  13. Porpiglia F, Fiori C, Amparore D, et al. Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up. *BJU Int.* 2019;123:1061–1069. <https://doi.org/10.1111/bju.14608>.
  14. Roehrborn CG, Gange SN, Shore ND, et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. *J Urol.* 2013;190:2161–2167. <https://doi.org/10.1016/j.juro.2013.05.116>.
  15. Nikhil Gupta, Tyson Rogers, Bradley Holland, Sevann Helo, Danuta Dynda, McVary Kevin T. Three-year treatment outcomes of water vapor thermal therapy compared to doxazosin, finasteride and combination drug therapy in men with benign prostatic hyperplasia: cohort data from the MTOPS trial. *J Urol.* 2018;200:405–413. <https://doi.org/10.1016/j.juro.2018.02.3088>.
  16. McVary KT, Rogers T, Roehrborn CG. Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. *Urology.* 2019;126:171–179. <https://doi.org/10.1016/j.urolgy.2018.12.041>.
  17. Chung A, Woo HH. Preservation of sexual function when relieving benign prostatic obstruction surgically: can a trade-off be considered? *Curr Opin Urol.* 2016;26:42–48. <https://doi.org/10.1097/MOU.0000000000000247>.
  18. Leong JY, Patel AS, Ramasamy R. Minimizing sexual dysfunction in BPH surgery. *Curr Sex Health Rep.* 2019;11:190–200. <https://doi.org/10.1007/s11930-019-00210-1>.
  19. De Nunzio C, Cantiello F, Fiori C, et al. Urinary and sexual function after treatment with temporary implantable nitinol device (iTind) in men with LUTS: 6-month interim results of the MT-06-study. *World J Urol.* 2020. <https://doi.org/10.1007/s00345-020-03418-2>.
  20. Riedinger CB, Fantus RJ, Matulewicz RS, Werntz RP, Rodriguez JF, Smith ND. The impact of surgical duration on complications after transurethral resection of the prostate: an analysis of NSQIP data. *Prostate Cancer Prostatic Dis.* 2019;22:303–308. <https://doi.org/10.1038/s41391-018-0104-3>.
  21. Mayer EK, Kroeze SGC, Chopra S, Bottle A, Patel A. Examining the “gold standard”: a comparative critical analysis of three consecutive decades of monopolar transurethral resection of the prostate (TURP) outcomes. *BJU Int.* 2012;110:1595–1601. <https://doi.org/10.1111/j.1464-410X.2012.11119.x>.
  22. Wager TD, Atlas LY. The neuroscience of placebo effects: connecting context, learning and health. *Nat Rev Neurosci.* 2015;16:403–418. <https://doi.org/10.1038/nrn3976>.
  23. Welliver C, Kottwitz M, Feustel P, McVary K. Clinically and statistically significant changes seen in sham surgery arms of randomized, controlled benign prostatic hyperplasia surgery. *J Urol.* 2015;194:1682–1687. <https://doi.org/10.1016/j.juro.2015.06.091>.